ST. PAUL, Minn., April 11, 2012 /PRNewswire/ -- Gamma Pharmaceuticals, Inc. (PINKSHEETS: GMPM) reached a milestone in its strategic plan for the current fiscal year: The Company has accepted its first order for a Male Enhancement product for export to Mexico. Gamma's customer is a large commercial operation in Mexico with distribution coverage and access to more than 15,000 retail locations. The contract governing this relationship has a two-year term with automatic extensions, creating a long term opportunity for Gamma in this important market. A full range of Gamma's products are under discussion and commercial review is underway.
Joseph Cunningham Gamma's President commented, "Our customer is established and well positioned to provide full national retail coverage. The Mexican market is large and a gateway for other national territories in Latin America."
Separately, Gamma is announcing it has developed a proprietary, fast acting Male Enhancement oral GEL and is in the late stages of product testing. Gamma is leveraging the Company's proprietary Gel Delivery Technology™ to solve a common complaint regarding the array of current products in the Erectile Dysfunction and Male Performance market: slow response time. Typically a pill or tablet can take up to 45 minutes to be effective. Gamma's GEL Delivery Technology™ enables active ingredients to be absorbed up to 80 times faster than a pill or capsule, significantly compressing the time from ingestion to erection and providing Gamma with a clear competitive advantage. Over the past five years, sales for Male Enhancement products have steadily increased, exceeding $4.0 billion in 2011. Gamma views its fast acting entrant in this rapidly growing market as having the potential to gain meaningful market share.
Joseph Cunningham, Gamma's President commented, "Gamma's focus on alternative delivery systems for everyday health and wellbeing make the Male Enhancement market a natural opportunity for our proprietary knowledge and expertise. We are very excited to begin our export program to Mexico and beyond. We anticipate strong growth in this category and expansion of the product mix in the months ahead."
About Gamma Pharmaceuticals, Inc.
Gamma Pharmaceuticals, Inc. (www.gammapharma.com) is a marketing and product formulation company focused on alternative delivery systems for everyday health and wellness. Gamma sells its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutraceuticals, OTC pharmaceutical products and personal care products in the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ nutritional supplements featuring the call to action, "You've made a brilliant choice for your nutrition;" SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Gamma Energy Products™ a high performance supplement featuring the call to action, "Get Your Gamma On." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs support Gamma's product sales and retail partners.
At present Gamma manufactures in North America and distributes in the United States and Mexico. Gamma's products utilize proprietary "Gel Delivery Technology®", to create innovative gel product forms that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, superior texture, convenience and great taste. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well-being, Menopause Symptoms and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKUs and holds licenses for 9 SKUs in China.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: Gamma Pharmaceuticals, Inc.
Joe Cunningham, President ([email protected])
Direct: (651) 204 2048
SOURCE Gamma Pharmaceuticals, Inc.